Baxter opens new biologics facility in Singapore

Baxter has announced the launch of its first advanced recombinant biologics facility in Singapore, strengthening its global leadership in haemophilia treatment.

The state-of-the-art facility has been created to help the company ramp up its production of haemophilia therapies such as Advate, having received European regulatory approval to produce this drug at the site earlier this year.

In addition to this announcement, the firm confirmed expansion plans for a new recombinant protein processing suite, which will initially process the haemophilia B therapy Rixubis.

When fully operational, the overhauled Singapore site will be the primary global commercial processing facility for Rixubis and will also support production of the company's investigational extended half-life recombinant FVIII treatment BAX 855 upon regulatory approval.

Dr Ludwig Hantson, president of Baxter BioScience, said: "The opening of the Singapore facility reinforces our continued commitment to expanding access to advanced, high quality treatments for patients around the world."

Advate is continues to be the most prescribed full-length recombinant FVIII therapy worldwide, with more than ten years of real-world experience and over 17 billion units distributed.